1. Search Result
Search Result
Results for "

bleomycin

" in MedChemExpress (MCE) Product Catalog:

39

Inhibitors & Agonists

1

Peptides

1

Inhibitory Antibodies

10

Natural
Products

2

Recombinant Proteins

3

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-17565
    Bleomycin sulfate
    Maximum Cited Publications
    100 Publications Verification

    bleomycin sulfate

    DNA/RNA Synthesis Antibiotic Cancer
    Bleomycin sulfate is a DNA synthesis inhibitor. Bleomycin hydrochloride is a DNA damaging agent. Bleomycin sulfate is an antitumor antibiotic .
    Bleomycin sulfate
  • HY-17565A
    Bleomycin hydrochloride
    Maximum Cited Publications
    100 Publications Verification

    DNA/RNA Synthesis Antibiotic Cancer
    Bleomycin hydrochloride is a DNA synthesis inhibitor. Bleomycin hydrochloride is a DNA damaging agent. Bleomycin hydrochloride is an antitumor antibiotic .
    Bleomycin hydrochloride
  • HY-N10469

    Phleomycin F

    Antibiotic Cancer
    Bleomycin B4 (Phleomycin F) is an antibiotic. Bleomycin B4 has antitumor activity. Bleomycin B4 can be used for the research of cancer .
    Bleomycin B4
  • HY-N10470
    Bleomycin A5
    1 Publications Verification

    Pingyangmycin

    Apoptosis Infection Inflammation/Immunology Cancer
    Bleomycin A5 (Pingyangmycin) is an orally active glycopeptide antibiotics. Bleomycin A5 has a role as an antineoplastic agent, an apoptosis inducer and a bacterial metabolite .
    Bleomycin A5
  • HY-108345

    Antibiotic Cancer
    Bleomycin is a glycopeptide antibiotic. Bleomycin has potent antitumour activities against a range of lymphomas, head and neck cancers and germ-cell tumours. Bleomycin can be used for the research of cancer and chemotherapy .
    Bleomycin
  • HY-17565R

    DNA/RNA Synthesis Antibiotic Cancer
    Bleomycin (sulfate) (Standard) is the analytical standard of Bleomycin (sulfate). This product is intended for research and analytical applications. Bleomycin sulfate is a DNA synthesis inhibitor. Bleomycin hydrochloride is a DNA damaging agent. Bleomycin sulfate is an antitumor antibiotic .
    Bleomycin sulfate (Standard)
  • HY-125918

    Pingyangmycin hydrochloride

    Apoptosis Antibiotic Infection Cancer
    Bleomycin A5 (Pingyangmycin) hydrochloride is an anti-neoplastic glycoprotein antibiotic. Bleomycin A5 suppresses Drp1-mediated mitochondrial fission and induces apoptosis in human nasal polyp-derived fibroblasts. Bleomycin A5 hydrochloride has anticancer activities relying on its ability to produce RNA and DNA breaks, thus, leading to cell death ..
    Bleomycin A5 hydrochloride
  • HY-106364

    bleomycin PEP; Pepleomycin

    Antibiotic Cancer
    Peplomycin (Bleomycin PEP; Pepleomycin) is an antibiotic analogue of Bleomycin (HY-108345), with high antitumor effect and less pulmonary toxicity. Peplomycin induce apoptosis in oral squamous carcinoma cell line SSCKN cells and pulmonary fibrosis in rats .
    Peplomycin
  • HY-146646

    Antibiotic Infection Cancer
    Bleomycin A2, an antitumor antibiotic promoting DNA-degradation, is an aspartate/asparagine-β-hydroxylase (AspH) inhibitor with an IC50 of 1.47 μM .
    Bleomycin A2
  • HY-148649

    Antibiotic Others
    Demethyl bleomycin A2 is a Bleomycin (HY-108345) congener. The DNA cleavage of demethyl bleomycin A2 is insensitive to the presence of 5-Methylcytidine (HY-113135) .
    Demethyl bleomycin A2
  • HY-120420

    Others Cancer
    N4Py is a pentadentate ligand, that forms a stable complex with metal ions, such as iron, platinum, and copper. N4py mimics the metal binding domains of iron-dependent antibiotics like Bleomycin(HY-17565), forms the DNA-cleaving FeII-N4Py complexes, generates reactive oxygen species (ROS), and causes oxidative damage in cells. N4py can be used in cancer research .
    N4Py
  • HY-111432

    Ras Others
    CCG-232601 (compound 8f) is a potent and orally active Rho/MRTF/SRF transcriptional pathway inhibitor. CCG-232601 inhibits the development of Bleomycin-induced dermal fibrosis in mice. CCG-232601 has the potential for the research of antifibrotic for systemic scleroderma .
    CCG-232601
  • HY-155328

    HDAC Inflammation/Immunology
    GK444 (Compound 15a) is a HDAC1/2 inhibitor (IC50: 100 and 92 nM for HDAC1/2 respectively). GK444 inhibits Caco-2 cells with IC50 of 4.1 μM. GK444 also reduces TGF-β1 induced COL1A1 mRNA levels in primary normal human lung fibroblasts. GK444 inhibits Bleomycin (HY-108345)-induced lung fibrosis in mice .
    GK444
  • HY-N3196

    Bacterial Infection Inflammation/Immunology
    Neotuberostemonine, one of the main antitussive alkaloids in the root of Stemona tuberosa Lour, attenuates bleomycin-induced pulmonary fibrosis by suppressing the recruitment and activation of macrophages .
    Neotuberostemonine
  • HY-137992

    Others Inflammation/Immunology
    Aucuparin, a natural product found in Sorbus aucuparia, inhibits pulmonary fibrosis in a bleomycin (BLM)-induced lung fibrosis mouse model. Anti-inflammatory activity .
    Aucuparin
  • HY-111428

    PLM D1

    Antibiotic Infection
    Phleomycin D1 (PLM D1), a glycopeptide antibiotic, is a member of the Bleomycin/Phleomycin family. Phleomycin D1 causes cell death by binding and cleaving DNA .
    Phleomycin D1
  • HY-126490

    Bacterial Antibiotic DNA/RNA Synthesis Infection Cancer
    Phleomycin is an anticancer glycopeptide antibiotic found in Streptomyces verticillus, which cause DNA cleavage. Phleomycin binds and intercalates DNA to damage the integrity of the double helix, which is similar to Bleomycin (HY-17565A) .
    Phleomycin
  • HY-162929

    TGF-β Receptor Inflammation/Immunology
    TP-DEA2, a predictable-release Triptolide (HY-32735) prodrug, block Bleomycin-induced pulmonary fibrosis and inflammation. TP-DEA2 significantly inhibits α-SMA production .
    TP-DEA2
  • HY-N0697
    Crocin
    5+ Cited Publications

    Crocin I

    Endogenous Metabolite JAK Apoptosis Neurological Disease Inflammation/Immunology Cancer
    Crocin (Crocin I) is an orally active natural product that can be isolated from the stigma of Crocus sativus. Crocin inhibits tumor cell proliferation and promotes apoptosis through JAK pathway. Crocin has anti-inflammatory, antioxidant and antitumor activities .
    Crocin
  • HY-155329

    HDAC Inflammation/Immunology
    GK718 is a HDAC1/3 inhibitor (IC50: 259 and 139 nM respectively). GK718 increased acetylated histone H3 level in cells. GK718 inhibits Bleomycin (HY-108345) induced pulmonary fibrosis in mice .
    GK718
  • HY-P1931

    Uteroglobin(39-47)

    Interleukin Related Inflammation/Immunology
    Antiflammin-1 is an anti-inflammatory peptide 1 (MQMKKVLDS). Antiflammin-1 is a derivative of uteroglobin. Antiflammin-1 has anti-inflammatory and antifibrotic actions in bleomycin (HY-108345)-induced lung injury .
    Antiflammin-1
  • HY-119160

    PAI-1 Inflammation/Immunology Cancer
    TM5007 is a poent and orally active inhibitor of plasminogen activator inhibitor-1 (PAI-1) with an IC50 of 29 μM. TM5007 enhance fibrinolysis activity and inhibits coagulation. TM5007 also prevents the fibrotic process initiated by bleomycin in mouse lung .
    TM5007
  • HY-12514

    Ser/Thr Protease
    NK3201 is an orally active chymase inhibitor (IC50: 2.5, 1.2, and 28 nM for human, dog and hamster chymase). NK3201 inhibits Bleomycin (HY-17565)-induced pulmonary fibrosis. NK3201 inhibits vascular proliferation in grafted vein .
    NK3201
  • HY-W803134

    TGF-beta/Smad Inflammation/Immunology
    E/Z-SIS3 free base exhibits an inhibitory efficacy against smad3, exhibits an anti-fibrotic and anti-inflammatory effect through a TGF-β/smad3 signaling pathway .
    (E/Z)-SIS3 free base
  • HY-147936

    MMP Inflammation/Immunology
    TP0556351 is a potent and selective matrix metalloproteinase-2 (MMP2) inhibitor with an IC50 value of 0.2 nM. TP0556351 reduces the amount of collagen in the lungs of a Bleomycin-induced pulmonary fibrosis mouse model. TP0556351 can be used for researching idiopathic pulmonary fibrosis (IPF) .
    TP0556351
  • HY-N8278

    Thrombin Cardiovascular Disease Inflammation/Immunology
    Dermatan sulphate sodium is a glycosaminoglycan and thrombin inactivator with antithrombotic activity. Dermatan sulphate sodium selectively catalyzes the inactivation of thrombin by heparin cofactor II and does not interact with antithrombin III. Dermatan sulphate sodium is highly bioavailable and also reduces Bleomycin (HY-108345)-induced pulmonary fibrosis damage .
    Dermatan sulphate sodium
  • HY-143420

    Phosphodiesterase (PDE) Inflammation/Immunology
    ATX inhibitor 15 (compound 30), a indole-based carbamate derivative, is a potent autotaxin (ATX) inhibitor with an IC50 of 2.17 nM. ATX inhibitor 15 inhibits in vivo ATX and the gene expression of pro-fibrotic factors. ATX inhibitor 15 has lung protection effects in Bleomycin challenged mice lung fibrosis model .
    ATX inhibitor 15
  • HY-12678
    Entrectinib
    20+ Cited Publications

    NMS-E628; RXDX-101

    ROS Kinase Trk Receptor Anaplastic lymphoma kinase (ALK) Autophagy Cancer
    Entrectinib (NMS-E628) is an orally active, BBB-penetrated and centrally active inhibitor of TrkA/B/C, ROS1 and ALK, with IC50 values of 1, 3, 5, 12 and 7 nM, respectively. Entrectinib induces apoptosis and cycle arrest in cancer cells, has antitumor activity, and attenuates bleomycin-induced lung fibrosis in mice .
    Entrectinib
  • HY-155889

    Epigenetic Reader Domain Cancer
    IV-275 is an inhibitor of both BRG1 and BRM bromodomains. IV-275 increases the extent of DNA damage induced by Temozolomide (HY-17364) and Bleomycin (HY-108345). IV-275 inhibits the invasiveness of GBM cells. IV-275 enhances Temozolomide-induced cell death and the apoptosis-inducing activity of Temozolomide .
    IV-275
  • HY-155888

    Epigenetic Reader Domain Cancer
    IV-255 is a selective small molecule inhibitor of the BRG1 bromodomain. IV-255 increases the extent of DNA damage induced by Temozolomide (HY-17364) and Bleomycin (HY-108345). IV-255 inhibits the invasiveness of GBM cells. IV-255 enhances Temozolomide-induced cell death and the apoptosis-inducing activity of Temozolomide .
    IV-255
  • HY-158315

    Dipeptidyl Peptidase Inflammation/Immunology
    NZ-97 is an inhibitor for dipeptidyl peptidase 4 (DPP4) with an IC50 of 18 nM. NZ-97 exhibits a low initial plasma exposure with Cmax of 0.13 µM, which is eliminated in 8 h. NZ-97 ameliorates damage in the Lipopolysaccharides (HY-D1056)-induced lung injury and Bleomycin (HY-108345)-induced lung fibrosis in mice model .
    NZ-97
  • HY-12678R

    ROS Kinase Trk Receptor Anaplastic lymphoma kinase (ALK) Autophagy Cancer
    Entrectinib (Standard) is the analytical standard of Entrectinib. This product is intended for research and analytical applications. Entrectinib (NMS-E628) is an orally active, BBB-penetrated and centrally active inhibitor of TrkA/B/C, ROS1 and ALK, with IC50 values of 1, 3, 5, 12 and 7 nM, respectively. Entrectinib induces apoptosis and cycle arrest in cancer cells, has antitumor activity, and attenuates bleomycin-induced lung fibrosis in mice .
    Entrectinib (Standard)
  • HY-129407

    Ala-ala-phe-chloromethylketone tfa; N-Ala-Ala-Phe-CMK; Tripeptidyl Peptidase inhibitor II

    Others Infection
    AAF-CMK TFA (Ala-ala-phe-chloromethylketone tfa; N-Ala-Ala-Phe-CMK) is a subtilisin-type serine peptidase that removes tripeptides from the free NH2 termini of oligopeptides. AAF-CMK TFA is an irreversible inhibitor of TPPII and is typically used at concentrations of 10-100 μM. It does not significantly interfere with the chymotrypsin-like activity of the proteasome. AAF-CMK also inhibits bleomycin hydrolase and puromycin-sensitive aminopeptidase when used at a concentration of 50 μM.
    AAF-CMK TFA
  • HY-110126
    AR-C118925XX
    1 Publications Verification

    P2Y Receptor Inflammation/Immunology Cancer
    AR-C118925XX is a selective P2Y2 receptor antagonist. AR-C118925XX inhibits ATP-induced IL-6 production and phosphorylation of p38. AR-C118925XX also inhibits Bleomycin (HY-108345)-induced dermal fibrosis in mice. AR-C118925XX also inhibits ATP-induced tumor growth .
    AR-C118925XX
  • HY-162630

    HDAC Inflammation/Immunology
    HDAC6-IN-44 (compound H10) is a selective HDAC6 inhibitor with an IC50 value of 8.97 nM. HDAC6-IN-44 can inhibit the idiopathic pulmonary fibrosis (IPF) phenotype and exhibits antifibrotic activity. Additionally, HDAC6-IN-44 reduces fibrogenesis in a bleomycin-induced pulmonary fibrosis mouse model and demonstrates good metabolic stability. HDAC6-IN-44 holds promise for research in the field of idiopathic pulmonary fibrosis .
    HDAC6-IN-44
  • HY-12678S

    NMS-E628-d4; RXDX-101-d4

    ROS Kinase Trk Receptor Anaplastic lymphoma kinase (ALK) Autophagy Isotope-Labeled Compounds Cancer
    Entrectinib-d4 (NMS-E628-d4; RXDX-101-d4) is the deuterium labeled Entrectinib (HY-12678). Entrectinib is an orally active, BBB-penetrated and centrally active inhibitor of TrkA/B/C, ROS1 and ALK, with IC50 values of 1, 3, 5, 12 and 7 nM, respectively. Entrectinib induces apoptosis and cycle arrest in cancer cells, has antitumor activity, and attenuates bleomycin-induced lung fibrosis in mice .
    Entrectinib-d4
  • HY-12678S1

    NMS-E628-d8; RXDX-101-d8

    Isotope-Labeled Compounds Autophagy Anaplastic lymphoma kinase (ALK) Trk Receptor ROS Kinase Cancer
    Entrectinib-d8 (NMS-E628-d8; RXDX-101-d8) is a deuterated version of Entrectinib (HY-12678). Entrectinib (NMS-E628) is an orally available, blood-brain barrier permeable, central nervous system active TrkA/B/C, ROS1 and ALK inhibitor with IC50 values of 1, 3, 5, 12 and 12, respectively. 7 nM. Entrectinib induces apoptosis and cycle arrest in cancer cells, has anti-tumor activity, and also alleviates bleomycin-induced pulmonary fibrosis in mice .
    Entrectinib-d8
  • HY-103388

    COX TGF-β Receptor Glutathione Peroxidase Inflammation/Immunology
    NCX 466 is an orally active COX-1 and COX-2 inhibitor that exhibits anti-inflammatory and analgesic effects. Additionally, NCX 466 acts as a NO donor, exerting anti-inflammatory and antioxidant effects by improving microcirculation. NCX 466 significantly reduces the levels of transforming growth factor-β (TGF-β) and oxidative stress markers (such as thiobarbituric acid reactive substances (TBARS) and 8-hydroxy-2'-deoxyguanosine (8-OHdG)), and it decreases leukocyte recruitment during inflammation by reducing myeloperoxidase (MPO) activity, thereby preventing bleomycin (HY-108345)-induced pulmonary fibrosis in mice .
    NCX 466
  • HY-169177

    JNK Inflammation/Immunology
    JNK-1-IN-4 (Compound E1) is an inhibitor for JNK, that inhibits JNK-1, JNK-2 and JNK-3 with IC50s of 2.7, 19.0 and 9.0 nM, respectively. JNK-1-IN-4 inhibits the phosphorylation of c-Jun, and reduces the expression of TGF-β1-induced EMT marker proteins, such as fibronectin and α-SMA. JNK-1-IN-4 exhibits good pharmacokinetic characteristics with a bioavailability of 69%. JNK-1-IN-4 exhibits anti-fibrotic effect in Bleomycin (HY-17565)-induced mice idiopathic pulmonary fibrosis models .
    JNK-1-IN-4

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: